Bristol-Myers Squibb (BMY) Announces Additional CheckMate-032 Phase 1/2 Data in Previously Treated mUC Patients
- Nasdaq lags peers as Netflix, chip stocks drag; AmEx lifts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Jabil falls after placing CEO on paid leave amid internal investigation
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer
November 12, 2016 11:30 AM ESTData from CheckMate -032 showed a confirmed objective response rate of 38.5% in previously treated metastatic urothelial carcinoma patients who received the Opdivo 1 mg/kg and Yervoy 3 mg/kg regimen
No new safety signals identified with the Opdivo and Yervoy regimen
Results support further development of Opdivo plus Yervoy regimen in patients with metastatic urothelial carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)--... More